Skip to content
Psilocybin Research

Two federal agencies, one substance, two descriptions

The DEA and NIDA both publish on psilocybin, and they do not say the same thing. Both quoted in full, with where the disagreement actually is.

Federal sourcesReviewed

The short answer

The DEA lists “possible death” among psilocybin overdose effects. NIDA says psilocybin has “a low level of toxicity” and a low potential to cause fatal events. Both are current US federal publications and both are quoted exactly on this page. Of the five topics compared below, 1 is a genuine conflict and the rest are differences of remit — the DEA writes for enforcement, NIDA summarises research. Whoever is arguing with you about psilocybin is citing one of these two pages, and it is worth knowing what the other one says.

Side by side

What each one actually says

Every agency statement below is a direct quote. Our reading is labeled as ours and kept separate, because a page like this would be worthless if it paraphrased either side.

Can it kill you?

They disagree

DEA

Longer, more intense “trip” episodes, challenging experiences (physical and emotional), psychosis, and possible death.

NIDA

Psilocybin has a low level of toxicity, which means that it has a low potential of causing potentially fatal events like breathing problems or a heart attack.

Our reading

This is the real disagreement, and the wording matters. The DEA lists possible death among overdose effects; NIDA says the compound has low potential to cause fatal events. Both can be true at once, because they are describing different pathways. Psilocybin does not suppress breathing the way an opioid does — that is NIDA's point and it is the pharmacology. Deaths associated with psilocybin overwhelmingly involve something else: eating a poisonous mushroom by mistake, an accident during several hours of impaired judgment, or a cardiac event in someone already vulnerable. A reader should take from this that psilocybin is not a drug you overdose on in the ordinary sense, and that people have still died in circumstances involving it.

Is it addictive?

No conflict

DEA

The fact sheet does not address this.

NIDA

Research to date suggests that use of psilocybin does not typically lead to addiction.

Our reading

The DEA fact sheet does not address dependence, so there is nothing to compare. NIDA's position is unambiguous and is the one this site reports. It comes with a qualification NIDA also states: DSM-5 contains no psilocybin-specific substance use criteria, though it does include a diagnosis of other hallucinogen use disorder — so part of the absence is a fact about how the manual was written rather than a measurement of the drug.

What does it do in the short term?

No conflict

DEA

Nausea, vomiting, muscle weakness, and lack of coordination. […] hallucinations and an inability to discern fantasy from reality. Panic reactions and a psychotic-like episode also may occur.

NIDA

The research topic page does not address this.

Our reading

The DEA's acute list is accurate and is not softened anywhere in the research literature. Nausea and vomiting are common. Loss of coordination for several hours is why supervised programs require someone in the room. Panic and psychotic-like reactions are the acute events trials screen hardest to prevent. Nothing on this list is disputed.

Supervised versus unsupervised use

No conflict

DEA

The fact sheet does not address this.

NIDA

The risk of mental health problems such as psychosis or suicidality in supervised clinical settings among people who participate in research on psilocybin is low. However, poor mental health outcomes may be more likely with use outside of clinical settings.

Our reading

This single sentence carries more of the site's editorial position than anything else either agency publishes. Almost every reassuring number in the psilocybin literature comes from supervised sessions with screened participants, and NIDA says plainly that it does not transfer to use outside that setting. Any claim about safety that does not say which of the two it describes is incomplete.

Misidentifying the mushroom

No conflict

DEA

Abuse of psilocybin mushrooms could also lead to poisoning if one of the many varieties of poisonous mushrooms is incorrectly identified as a psilocybin-containing mushroom.

NIDA

The research topic page does not address this.

Our reading

The clearest point of agreement in spirit, and the risk least discussed by anyone selling anything. It is not pharmacological at all — no supervised program carries it, because the program supplies the substance. It applies entirely to picking mushrooms, and the species most often confused with small Psilocybe contain amatoxins, which cause liver failure. Our safety page carries a photograph of one for exactly this reason.

Why they differ, and why that is not a scandal

It would be easy to write this page as an exposé and it would be wrong. The DEA administers a schedule and publishes material aimed at enforcement and prevention; NIDA funds research and summarises what it finds. Those are different jobs and they produce different documents about the same molecule.

What is worth noticing is how the two get used. Someone arguing psilocybin is dangerous quotes the DEA line about possible death. Someone arguing it is safe quotes NIDA on low toxicity. Both are citing the federal government accurately and neither mentions that the other page exists.

The honest position sits between them and is narrower than either camp implies. Psilocybin is not a drug people overdose on in the way that phrase usually means — there is no respiratory depression, and that is a settled pharmacological fact. It is also not harmless: people have died in circumstances involving it, almost always through misidentified mushrooms, accidents during hours of impaired coordination, or cardiac events in people who were already at risk. Those are real deaths and none of them is an argument that the compound is directly lethal.

Safety and contraindications in fullCommonly misreportedFederal policy in 2026

Common questions

Questions about the federal position

What does the DEA say about psilocybin?
The DEA drug fact sheet describes acute effects as nausea, vomiting, muscle weakness and lack of coordination, alongside hallucinations, panic reactions and possible psychotic-like episodes. Under overdose it lists longer and more intense episodes, challenging experiences, psychosis and possible death. It separately warns that mistaking a poisonous mushroom for a psilocybin-containing one is itself a route to poisoning.
What does NIDA say about psilocybin?
The National Institute on Drug Abuse states that psilocybin has a low level of toxicity, meaning a low potential to cause fatal events such as breathing problems or a heart attack, and that research to date suggests use does not typically lead to addiction. It also states that the risk of psychosis or suicidality in supervised clinical settings is low, while poor mental health outcomes may be more likely outside clinical settings.
Can you die from psilocybin?
The two agencies word this differently and both are describing something real. Psilocybin does not suppress breathing the way an opioid does, which is what NIDA's low-toxicity statement refers to, and it is not a drug people overdose on in the ordinary sense. Deaths associated with it overwhelmingly involve something else — eating a misidentified poisonous mushroom, an accident during hours of impaired coordination, or a cardiac event in someone already vulnerable. Neither agency describes psilocybin as directly lethal at the doses used in research.
Why do two federal agencies describe the same drug differently?
Because they have different jobs. The DEA administers the controlled substances schedule and publishes enforcement-oriented fact sheets. NIDA funds and summarises research. Neither is misrepresenting anything; they are answering different questions, and a reader who only ever sees one of them gets a partial picture that the other would complete.
Is psilocybin still Schedule I?
Yes. Psilocybin remains a Schedule I controlled substance under federal law nationwide, and no FDA-approved psilocybin medicine exists. State programs in Oregon and Colorado operate under state law only and do not change federal status.

References

  1. 1.US Drug Enforcement Administration. Psilocybin drug fact sheet.The enforcement view, and useful precisely because it is not the research view. It lists overdose effects as longer and more intense episodes, challenging experiences, psychosis “and possible death”, and separately warns that misidentifying a poisonous mushroom is itself a route to poisoning. The second point is the one both agencies agree on.
  2. 2.National Institute on Drug Abuse. Psilocybin (Magic Mushrooms). NIDA research topics. Published 24 January 2024; page modified 6 March 2026.A US government overview that states both halves plainly: psilocybin typically raises blood pressure and heart rate, which may be dangerous for people with heart conditions, while the risk of psychosis or suicidality in supervised clinical settings is low. It also states that research to date suggests use does not typically lead to addiction, and that DSM-5 contains no psilocybin-specific substance use criteria. A topic summary, not primary data — it reports no effect sizes.